China approves three Gilead remdesivir patents for COVID-19 treatment
27-02-2020
J&J, HHS sign expanded deal to find COVID-19 vaccine
14-02-2020
Lightspring / Shutterstock.com
A state-run institution in China has applied for a patent on the use of an experimental Gilead Sciences drug, which scientists believe may be able to fight the coronavirus outbreak that has killed hundreds.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Wuhan Institute of Virology of the China Academy of Sciences, Gilead Sciences, coronavirus, experimental drugs, remdesivir, patent application
